11 news items
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
SNGX
16 May 24
as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
SNGX
10 May 24
million in net proceeds from our recent financing and our non-dilutive government funding, we continue to manage cash burn very carefully to achieve
Soligenix to Present at Upcoming Conferences
SNGX
6 May 24
supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
SNGX
25 Apr 24
a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees
Soligenix Announces Pricing of $4.75 Million Public Offering
SNGX
18 Apr 24
with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction
m9hskflzxudf3b37cev68q0 bs8m
SNGX
16 Apr 24
. In addition, financial and regulatory benefits are available including government grants to conduct clinical trials, waiver of FDA user fees, and certain
lo4608pokhwaojg3lb2w167kxq3vbbcv1xxn4uu0p53gp4hz98
SNGX
15 Apr 24
Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver
ldacok t9pxn0mlyyzekgz0l6nihb9w
SNGX
15 Apr 24
of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential
5wdl5n7m4ej46izx72
SNGX
11 Apr 24
positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials
x5z74j08n090f428cb3z3h5p0uy4efr6l2qr
SNGX
3 Apr 24
as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute
a4a3rpcooc ge21d
SNGX
15 Mar 24
at December 31, 2023, not including our non-dilutive government funding, we are managing cash burn very carefully in order to achieve our near-term
- Prev
- 1
- Next